The competitive advantage exhibited by Paqr8-OE, and competitive disadvantage exhibited by Paqr8-KO, tumor cells following Her2 downregulation could potentially result from Paqr8-mediated differences in cell survival, proliferation, or both. This evidence concerns the gene ERBB2 and neoplasm.